Clinical trials
Resistant Cancer clinical trials
Below are recruiting resistant cancer clinical trials, each written for real people, not researchers. We’re tracking 405 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06828263Recruiting
Imaging markers during PSMA therapy for prostate cancer
This trial is testing a new imaging approach during treatment with a radioactive drug (Lu-PSMA) for men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to see if imaging changes can help predict how well the treatment is working.
GrenobleAges 18 years+ - NCT06815497RecruitingPhase 2
Telmisartan plus chemo for platinum-resistant ovarian cancer
This trial tests adding telmisartan (a blood pressure medicine) to standard chemotherapy for people with ovarian cancer that no longer responds to platinum-based drugs. The goal is to see if the combination can help control the cancer better.
Lebanon, New HampshireAges 18 years+ - NCT06785636RecruitingPhase 1/Phase 2
New drug combination for advanced prostate cancer
This study tests a new drug (pocenbrodib) alone or combined with another hormone therapy (darolutamide) for men with advanced prostate cancer that has spread. It is for those who have already tried Pluvicto and one other hormone therapy, but not yet chemotherapy.
Fountain Valley, CaliforniaAges 18 years+ - NCT06242509Recruiting
Akkermansia bacteria in prostate cancer
This trial looks at whether a specific gut bacterium, Akkermansia muciniphila, is linked to how well hormone therapy works in men with advanced prostate cancer that no longer responds to standard hormone treatment. You may join if you are about to start a new type of hormone therapy.
ParisAges 18–100 - NCT06067503RecruitingPhase 2
PET scan to detect hormone therapy resistance in breast cancer
This trial tests a new PET scan (called FFNP) to see if it can find which breast cancers stop responding to hormone therapy early. It's for people with advanced hormone-receptor-positive breast cancer who are starting a new endocrine treatment.
Madison, WisconsinAges 18 years+ - NCT05413850RecruitingPhase 1/Phase 2
Lu-177 PSMA drug study for advanced prostate cancer
This early-stage study tests a radioactive prostate cancer medicine that targets PSMA (a protein on prostate cancer cells). It aims to see how well the treatment works and how safe it is for men whose cancer has spread and shows PSMA on a scan.
Miami, FloridaAges 18 years+ - NCT05125016RecruitingPhase 1/Phase 2
Study drug for advanced prostate cancer after standard treatments
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
Palo Alto, CaliforniaAges 18 years+ - NCT04946370RecruitingPhase 1/Phase 2
Pembrolizumab plus prostate cancer drug, with or without radiation
This early-phase trial tests pembrolizumab (an immune therapy) plus an androgen-receptor–blocking prostate cancer drug, and possibly a targeted radiation treatment. It’s for men with prostate cancer that has spread and keeps worsening despite standard hormone therapy, aiming to shrink tumors and improve control of the disease.
Boston, MassachusettsAges 18 years+ - NCT04886986RecruitingPhase 1
Testing a targeted radiation pill for advanced prostate cancer
This Phase 1 trial tests a small-molecule treatment that carries radioactive material to help treat prostate cancer that has spread and keeps growing despite standard hormone-blocking treatment. It’s mainly looking to find a safe dose and see how well the approach works in people with limited treatment options.
Brooklyn, New YorkAges 18–99 - NCT04221542RecruitingPhase 1
AMG 509 for advanced, hormone-resistant prostate cancer
This trial tests AMG 509, a study drug, in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite lowering testosterone). It’s for people whose cancer has progressed after certain hormone tablets and possibly chemotherapy, aiming to shrink tumors and control the disease safely.
Duarte, CaliforniaAges 18 years+ - NCT06844383RecruitingPhase 2
Talazoparib with or without enzalutamide for prostate cancer after prior treatment
This study tests a drug called talazoparib, either alone or combined with enzalutamide, in people with prostate cancer that has spread and has a specific genetic change. The goal is to see if this treatment can help control the cancer after previous therapies have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT04585958RecruitingPhase 1
Combination treatment for HER2-positive cancers and resistant ovarian cancer
This trial tests a new combination of two drugs, DS-8201a and olaparib, for people with cancers that have a protein called HER2, and for those with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can shrink or control the cancer.
Phoenix, ArizonaAges 18 years+ - NCT07189871RecruitingPhase 1/Phase 2
Targeted radiation therapy for advanced solid tumors
This study tests a new radioactive treatment (177Lu-BetaBart) for people with certain advanced solid tumors that have stopped responding to standard treatments. It aims to see if this targeted therapy can slow or stop tumor growth.
Dothan, AlabamaAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT06469281RecruitingPhase 1
A new immune cell therapy for recurring ovarian cancer
This early-phase trial tests a new immune cell therapy called 27T51, which targets a protein called MUC16 found on ovarian cancer cells. The study is for people with recurrent or treatment-resistant ovarian, primary peritoneal, or fallopian tube cancer to see if the therapy is safe and works when given alone or with other treatments.
Boston, MassachusettsAges 18 years+ - NCT06526299RecruitingPhase 2
Higher dose of targeted radiation for prostate cancer with low PSMA levels
This trial tests a higher dose of a radioactive drug (177Lu-PSMA-617) for men whose prostate cancer has spread and does not produce much of a protein called PSMA on scans. The goal is to see if a stronger dose can work better than the standard dose.
San Francisco, CaliforniaAges 18 years+ - NCT06610825RecruitingPhase 2
Enhertu for prostate cancer resistant to hormone therapy
This trial is testing a drug called Enhertu for men whose prostate cancer has spread and is no longer responding to hormone treatments. You may join if you have a tumor sample that can be tested for a protein called HER2.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06960720Recruiting
Weight lifting program for breast cancer fatigue
This trial tests whether a 3-month resistance exercise program (like lifting weights) can help reduce fatigue in women who have had breast cancer. You may be eligible if you were diagnosed with non-metastatic breast cancer 1-3 years ago and feel tired, even if only a little.
Morgantown, West VirginiaAges 18 years+ - NCT05888532RecruitingPhase 1/Phase 2
Testing a copper-based scan and treatment in advanced cancers
This Phase 1/2 trial studies a copper-labeled medicine called 64Cu-GRIP B in people with advanced, metastatic cancers. It may help doctors see where cancer is and how well the drug works, especially alongside immune checkpoint therapy for some cancer types.
San Francisco, CaliforniaAges 18 years+ - NCT06083324Recruiting
Exercise program to improve strength and mobility after cancer
This study tests a personalized exercise program using resistance training (lifting weights) to help cancer survivors rebuild strength, improve body composition, and move better after treatment. It is designed for people who are ready to start exercising safely and want to regain function.
Pittsburgh, PennsylvaniaAges 20–89 - NCT06792552RecruitingPhase 1
Study of SIM0505 for advanced solid tumors
This trial tests a new drug called SIM0505 for people with advanced solid tumors that have not responded to standard treatments. The study looks at different cancer types, including ovarian cancer, kidney cancer, uterine cancer, and lung cancer, to see if SIM0505 can help shrink tumors or slow their growth.
Orlando, FloridaAges 18 years+ - NCT07677254Recruiting
Real world study of prostate cancer treatments
This study looks at real-world data from men with metastatic castration-resistant prostate cancer (mCRPC) to understand what treatments they receive and how they do. It may help doctors learn more about which treatments work best.
East Hanover, New JerseyAges 18–115 - NCT07871110RecruitingPhase 2
New pill combined with hormone therapy for advanced prostate cancer
This study tests a new pill (TT00420) taken with standard hormone therapy for prostate cancer that has spread and is no longer responding to initial hormone treatment. The goal is to see if the combination can help slow the cancer's growth and is safe.
Fuzhou, FujianAges 18 years+ - NCT07451795RecruitingPhase 2
SHR-1701 with targeted radiation for advanced prostate cancer
This trial tests a new drug called SHR-1701 combined with a precise type of radiation (SBRT) for men with prostate cancer that has spread and is no longer responding to hormone therapy. The goal is to see if this combination can help control the cancer.
FujianAges 18–80
Hear when a new Resistant Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for resistant cancer?
- Yes. Clin2 currently lists 405 recruiting resistant cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a resistant cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a resistant cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Castration-resistant Prostate Cancer
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Non Small Cell Lung Cancer
- Castration-resistant Prostate Cancer
- Platinum-resistant Ovarian Cancer
- Castrate Resistant Prostate Cancer
- Gastric Cancer, Gastroesophageal Junction Cancer
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.